<DOC>
	<DOCNO>NCT00429806</DOCNO>
	<brief_summary>The purpose study evaluate systemic bioavailability DHEA metabolites pharmacokinetics vaginal suppository four different DHEA concentration .</brief_summary>
	<brief_title>DHEA Bioavailability Following Administration Vaginal Suppositories Post-Menopausal Women With Vaginal Atrophy</brief_title>
	<detailed_description>Humans , unique among animal specie adrenal secrete large amount inactive precursor steroid dehydroepiandrosterone ( DHEA ) especially sulfate DHEA-S . The marked reduction formation DHEA-S adrenal age result dramatic fall formation androgens estrogens peripheral target tissue , situation propose associate age-related disease include skin atrophy , insulin resistance obesity . Much attention give benefit DHEA administer postmenopausal woman , especially bone , skin , vagina well oral well percutaneous administration precursor steroid . Therefore , study proposes evaluate systemic bioavailability effectiveness 1.3 mL vaginal suppository DHEA 4 different concentration ( 0.0 % , 0.5 % , 1.0 % et 1.8 % ) follow 1 week administration vaginal suppository post-menopausal woman vaginal atrophy . This phase I , randomize , placebo-controlled , double-blind study .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Postmenopausal woman , Experiencing one symptom vaginal atrophy ( vaginal dryness , vaginal and/or vulvar irritation/itching , dysuria , vaginal pain associate sexual activity vaginal bleeding associate sexual activity , Women low maturation index vaginal pH 5 , Endometrial thickness 4 mm less transvaginal ultrasonography , Body weight within 18.5 32.0 accord body mass index . Undiagnosed abnormal genital bleeding , Active history thromboembolic disease , Significant metabolic endocrine disease , Significant complication previous hormonal therapy , Use hormonal implant within 6 month prior study entry , Use oral estrogen , progestin DHEA 8 week prior baseline , Use natural ( phytoestrogens ) herbal product 2 week prior baseline , Chronic use corticosteroid , Hypertension control standard therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Vaginal atrophy</keyword>
	<keyword>DHEA</keyword>
	<keyword>Prasterone</keyword>
	<keyword>Menopause</keyword>
</DOC>